<DOC>
	<DOCNO>NCT01097590</DOCNO>
	<brief_summary>The purpose study determine whether treatment novel leukapheresis column safe effective patient moderate severe ulcerative colitis .</brief_summary>
	<brief_title>A Study Evaluate Leukapheresis Treatment Patients With Ulcerative Colitis</brief_title>
	<detailed_description>Ulcerative colitis ( UC ) chronic relapse disease characterize superficial inflammation colonic epithelium . The inflammation maintain continuous supply inflammatory cell circulate blood intestinal mucosa . Existing therapy e.g . corticosteroid immunosuppressant inadequate overall long-term remission rate 50-60 % . Those treatment also associate severe side effect need new therapy . The aim study investigate novel leukapheresis treatment potential reduce number inflammatory cell home gut mucosa . By draw blood patient pas investigational column inflammatory cell remove . The blood , deplete inflammatory cell , return patient . The treatment thus enable down-regulation inflammation consequently inflammation heal . The treatment call Tailored leukapheresis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Clinical diagnosis active , moderatetosevere , Ulcerative Colitis . Exclusion criterion ; Local intestinal treatment suppository , enemas clysmas last 4 week Current daily smoking habit Other severe disease detail protocol History hypersensitivity heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>leukapheresis treatment</keyword>
</DOC>